|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Pfizer Inc - SWOT Analysis |
|
|
|
|
€ 100,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Mars 2008 |
Taille du document : |
46 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Chinese Markets for Pharmaceuticals
225 pages | Janvier 2002 |
China's demand for pharmaceuticals has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic |
3 500,00 €
|
| |
| |
The Global Parallel Trade Outlook 2001 - 2006: A Country-by-Country Analysis
188 pages | Septembre 2001 |
Global Parallel Trade Outlook 2001: A country-by-country analysis, a new report by Reuters Business Insight, provides a detailed update on the status of parallel trade in the global marketplace.
1 200,00 €
|
|
| |
| |
Antisense Therapy: Technical Aspects and Commercial Opportunities
334 pages | Mars 2000 |
Antisense therapy interferes with the expression of disease-causing proteins, thus offering a direct and selective intervention in the disease process.
Besides the well known oligonucleotides ( |
955,00 €
|
| |
| |
Bridging the Pharmaceutical Earnings gap: Key Strategies in the race for growth
173 pages | Mars 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once near unrestricted revenue expansion existed, external pressures now act in unison |
955,00 €
|
| |
| |
Regulatory Affairs: Paths to Approval
113 pages | Février 1999 |
Area Specific Chapters : The regulatory systems governing clinical trials and drug approvals are examined for the US, Europe, and Australia, Canada and Japan, including analysis of the implicatio |
795,00 €
|
| |
| |
Patient Power in the Pharmaceutical Industry: The shift towards more informed, more powerful consumers of drugs
119 pages | Juin 1999 |
The dramatic rise in patient power in recent years presents a new and challenging opportunity to pharmaceutical companies, healthcare providers and governments alike.
A great need exists for ph |
795,00 €
|
| |
| |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century
189 pages | Octobre 2000 |
The Drug Discovery Outlook: Drivers of innovation in the 21st Century introduces and analyzes the five key enabling technologies and bioinformatics, which are currently driving pharmaceutical dru |
955,00 €
|
| |
| |
Pfizer's Recent Takeover
15 pages | Juillet 2002 |
On 15th July 2002, Pfizer announced the acquisition of Pharmacia in a stock-for-stock transaction valued at $60 billion, expanding the company's core strengths in pharmaceuticals and health care.
|
300,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets
214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals.
Mar |
795,00 €
|
| |
| |
The Pharmaceutical Mergers and Acquisitions Outlook 2001
128 pages | Octobre 2001 |
Pharmaceutical companies have recently undertaken extensive M&A activity to either build critical mass, create organic growth or through strategic alliances to build virtual mass.
The Pharmaceu |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Pfizer Inc - SWOT Analysis |
|
|
Datamonitor's Pfizer Inc - SWOT Analysis Company Profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Pfizer, one of the largest pharmaceutical companies, discovers, develops, manufactures and markets prescription medicines for humans and animals. The company operates in more than 150 countries. Pfizer is headquartered in New York City, New York and employs about 98,000 people. The company recorded revenues of $48,371 million during the fiscal year ended December 2006, an increase of 2% over 2005. The increase was primarily due to the strong performance by the company’s new products over the past three years. The operating profit of the company was $12,124 million during fiscal year 2006, an increase of 8.3% over 2005. The net profit was $19,337 million in fiscal year 2006, as compared to a net profit of $8,085 in 2005.
Scope of the Report
- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company’s history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement
Reasons to Purchase
- Support sales activities by understanding your customers’ businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors’ business structure, strategy and prospects
- Obtain the most up to date company information available
|
|
Table of Contents:
This product typically includes the following sections:
Key Facts
Company Overview
Business Description
Company History
Key Employees
Key Employee Biographies
Company View
SWOT analysis
Products & Services Listing
Products & Services Analysis
|
|
|
PPLSEN
|
|
|
|
|
